Showing 118 of 118on this page. Filters & sort apply to loaded results; URL updates for sharing.118 of 118 on this page
Tasisulam - Potent Anticancer Agent | APExBIO
Tasisulam | CAS:519055-62-0 | antitumor agent | High Purity ...
Tasisulam | ≥99%(HPLC) | Selleck | カスパーゼ 阻害剤&活性剤
Tasisulam effects in vitro. A, Calu-6 and A-375 cell sensitivity to ...
Tasisulam ≥98% (HPLC) | Sigma-Aldrich
Tasisulam | 他司磺胺 | Caspase | Apoptosis | TargetMol
Medchemexpress LLC HY-14804 10mg Medchemexpress, Tasisulam CAS:519055 ...
tasisulam | Semantic Scholar
Tasisulam |CAS:519055-62-0 Probechem Biochemicals
Tasisulam sodium | | 519055-63-1 | AdooQ®
Tasisulam displays dose-dependent antitumor activity, induces ...
Tasisulam Sodium | C11H5BrCl2NNaO3S2 | CID 23718384 - PubChem
Tasisulam – Tenova Pharma
High content imaging subpopulation analysis of tasisulam in vitro ...
Tasisulam | Tasisulam | 519055-62-0 | 天然产物（标准品）-百奥克睿官网
Maximum change in impedance fol- lowing tasisulam treatment of ECFCs ...
(PDF) A phase II study of tasisulam sodium (LY573636 sodium) as second ...
Total plasma tasisulam (LY573636) concentrations using lean body weight ...
(PDF) Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic ...
Kaplan-Meier graph of progression-free survival at the tasisulam target ...
Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression ...
(PDF) A phase I study of tasisulam sodium (LY573636 sodium), a novel ...
Tasisulam Sodium; CAS No:519055-63-1; LY573636
Tasisulam
Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients ...
A phase 2 study of tasisulam sodium (LY573636 sodium) as second‐line ...
他斯索兰/N(2,4-二氯苯甲酰基-5-溴噻吩-2-磺酰胺 Tasisulam 519055-62-0-四川省维克奇生物科技有限公司
A randomized, open‐label clinical trial of tasisulam sodium versus ...
Tasisulam 519055-62-0 | 東京化成工業株式会社
Tasisulam sodium | TargetMol
他斯索兰 Tasisulam,LY573636 Cas号：519055-62-0
Tasisulam(519055-62-0) 1H NMR spectrum
LY573636 (Tasisulam) | Apoptosis inducer | 519055-62-0 | AdooQ®
Design and Synthesis of E7820/Tasisulam Hybrids as Potential DCAF15 Binders
Tasisulam, an Antitumor Agent, Inhibits Mitotic Progression and Induces ...
Baseline demographics and disease characteristics for patients treated ...
LY573636 (Tasisulam) | Apoptosis inducer | LY573636 (Tasisulam)供应商 AdooQ®
Structure of the complex of DDA1-DDB1-DCAF15-RBM39 with SPLAMs. A ...
Chlorine in PDB 6q0v: Structure of DDB1-DDA1-DCAF15 Complex Bound to ...
a Chemical structures of lenalidomide. b Chemical structures of E7820 ...
Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9 ...
Anticancer sulfonamides target splicing by inducing RBM39 degradation ...
Tasisulam(LY573636) - CAS# 519055-62-0 – Xcess Biosciences
Tasisulam, ≥98% | CAS 519055-62-0 | Lancrix Chemicals
RCSB PDB - 6Q0V: Structure of DDB1-DDA1-DCAF15 complex bound to ...
LY573636 (Tasisulam) (Tasisulam) | CAS 519055-62-0 | AbMole BioScience ...
Synthesis of sulfondiimidamide derivatives of bioactive molecules. (a ...
Exploration of Novel Chemical Space: Synthesis and in vitro Evaluation ...
Safety Concerns Lead Lilly to Suspend Phase III Melanoma Trial
Recent advances in anticancer mechanisms of molecular glue degraders ...
Caspase抑制剂 | Caspase Inhibitor
(PDF) Physiologically Based Pharmacokinetic Modelling of Cytochrome ...
ACMEC Tasisulam,519055-62-0-实验室用品商城
A New, Practical One‐Pot Synthesis of Unprotected Sulfonimidamides by ...
Aryl-sulfonamide binding to DCAF15 a, Sketch of E7820 and its ...
Figure S5. A) Relative protein levels between untreated MOLM-13 cells ...
Articles | Genes & Genomics
RBM39 degradation causes changes in the cell cycle. A) The PRISM ...
Small Molecules Modulating Splicing for Use in Cancer Treatment ...
CR8-induced degradation of cyclin K correlates with DDB1 expression a ...
Overlaid Transcriptional and Proteome Analyses Identify Mitotic ...
Results from assessment of dose proportionality showing Cmax values ...
Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by ...
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes ...
Next Frontier: Molecular Glue Development - BOC Sciences
Haven't got a glue: Protein surface variation for the design of ...
Demonstration of mda-7/IL-24-mediated antiangiogenic activity by ...
【Cell Chemical Biology】降解型分子胶分子机制总结 - 知乎
他斯索兰「CAS号：519055-62-0」 – 960化工网
So How Does Temsirolimus Perform .20140726.190714 | PDF | Mycobacterium ...
SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal ...
Emerging degrader technologies engaging lysosomal pathways - PMC
Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs - PMC
药物发现│靶向蛋白降解，除了PROTAC，还有啥？
LY-573636 | 519055-63-1
Structural complementarity facilitates E7820-mediated degradation of ...
Chemical formula, skeletal formula and 3D ball-and-stick model of ...
Chemical Formula Skeletal Formula And 3d Ballandstick Model Of ...
